Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Systematic Financial Management LP

Systematic Financial Management LP raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 302.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 113,500 shares of the specialty pharmaceutical company's stock after acquiring an additional 85,315 shares during the quarter. Systematic Financial Management LP owned approximately 0.21% of Supernus Pharmaceuticals worth $4,104,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in SUPN. Barclays PLC lifted its holdings in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock worth $987,000 after acquiring an additional 2,121 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Supernus Pharmaceuticals by 5.4% during the 3rd quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company's stock valued at $8,899,000 after acquiring an additional 14,566 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 60.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 66,306 shares of the specialty pharmaceutical company's stock valued at $2,398,000 after purchasing an additional 25,004 shares in the last quarter. Finally, Wedge Capital Management L L P NC bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth $1,928,000.

Supernus Pharmaceuticals Stock Performance

SUPN stock traded down $0.16 during midday trading on Friday, reaching $31.88. The stock had a trading volume of 67,983 shares, compared to its average volume of 483,134. The firm has a fifty day simple moving average of $31.98 and a two-hundred day simple moving average of $34.79. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The stock has a market cap of $1.78 billion, a PE ratio of 29.77 and a beta of 0.74.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.